NEWBRY — Newbury Pharmaceuticals AB Share Price
Last trade - 00:00- SEK79.81m
- SEK66.95m
- SEK36.83m
- 21
- 22
- 50
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.14 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.78 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.37% | ||
| Return on Equity | -29.65% | ||
| Operating Margin | -29.1% | ||
Financial Summary
| Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | 2.83 | 5.52 | 10.27 | 36.83 | 73 | 141 | 135.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +200 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Newbury Pharmaceuticals AB is a Sweden-based pharmaceutical company for specialty prescription drugs. The Company’s existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.
Directors
- Last Annual
- August 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- September 30th, 2020
- Public Since
- February 4th, 2022
- No. of Employees
- 5
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 24,258,654
- Address
- Medicon Village, Scheeletorget 1, LUND, 223 81
- Web
- https://www.newburypharma.com
- Phone
- +46 46121120
- Auditors
- Ernst & Young AB
Upcoming Events for NEWBRY
Similar to NEWBRY
Apotea Sverige AB
OMX Nordic Exchange Stockholm
Axfood AB
OMX Nordic Exchange Stockholm
EQL Pharma AB
OMX Nordic Exchange Stockholm
Herno Gin AB
OMX Nordic Exchange Stockholm
Viva Wine AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 22:15 UTC, shares in Newbury Pharmaceuticals AB are trading at SEK3.29. This share price information is delayed by 15 minutes.
Shares in Newbury Pharmaceuticals AB last closed at SEK3.29 and the price had moved by -0.9% over the past 365 days. In terms of relative price strength the Newbury Pharmaceuticals AB share price has underperformed the FTSE Global All Cap Index by -3.38% over the past year.
There is no consensus recommendation for this security.
Find out moreNewbury Pharmaceuticals AB does not currently pay a dividend.
Newbury Pharmaceuticals AB does not currently pay a dividend.
Newbury Pharmaceuticals AB does not currently pay a dividend.
To buy shares in Newbury Pharmaceuticals AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK3.29, shares in Newbury Pharmaceuticals AB had a market capitalisation of SEK79.81m.
Here are the trading details for Newbury Pharmaceuticals AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: NEWBRY
Based on an overall assessment of its quality, value and momentum Newbury Pharmaceuticals AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Newbury Pharmaceuticals AB is SEK8.00. That is 143.16% above the last closing price of SEK3.29.
Analysts covering Newbury Pharmaceuticals AB currently have a consensus Earnings Per Share (EPS) forecast of SEK0.20 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Newbury Pharmaceuticals AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -15.32%.
As of the last closing price of SEK3.29, shares in Newbury Pharmaceuticals AB were trading -5.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Newbury Pharmaceuticals AB PE ratio based on its reported earnings over the past 12 months is 7.14. The shares last closed at SEK3.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Newbury Pharmaceuticals AB's directors